
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
WASHINGTON, D.C. 20549

FORM 6-K

**REPORT OF FOREIGN PRIVATE ISSUER PURSUANT
TO RULE 13a-16 or 15d-16 UNDER THE
SECURITIES EXCHANGE ACT OF 1934**

For the month of April, 2019

Commission File Number: 001-38452

MEREO BIOPHARMA GROUP PLC

(Translation of registrant's name into English)

**4th Floor, One Cavendish Place,
London, W1G 0QE, United Kingdom**
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

Mereo BioPharma Group plc

("Mereo" or the "Company")

Notification of Director Dealing

London, April 30, 2019 - Merco BioPharma Group plc (AIM: MPH), a clinical stage UK based biopharmaceutical company focused on rare diseases, received notification that on 29 April 2019, Denise Scots-Knight, Chief Executive Officer of Merco BioPharma, purchased 6000 American Depositary Shares (ADSs) at a total price of USD5.887 per ADS.

In addition, Richard Jones, Chief Financial Officer of Merco BioPharma, purchased 2025 American Depositary Shares (ADSs) at a price of USD6.04 per ADS.

The below announcement and notification is made in accordance with the EU Market Abuse Regulation. The form required under the EU Market Abuse Regulation follows.

1	Details of the person discharging managerial responsibilities							
a)	Name	Denise Scots-Knight						
2	Reason for the notification							
a)	Position/status	Chief Executive Officer						
b)	Initial notification/ Amendment	Initial notification						
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor							
a)	Name	Mereo BioPharma Group plc						
b)	LEI	213800U8JQHJIOS5AS09						
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted							
a)	Description of the financial instrument, type of instrument and identification code	MEREO BIOPHARMA GROUP PLC AMERICAN DEPOSITARY SHARES (ADSs)						
b)	Nature of the transaction	PURCHASE						
c)	Price(s) and volume(s)	<table><tr><td>Price(s)</td><td>Volume(s)</td></tr><tr><td>USD5.87</td><td>3000</td></tr><tr><td>USD5.90</td><td>3000</td></tr></table>	Price(s)	Volume(s)	USD5.87	3000	USD5.90	3000
Price(s)	Volume(s)							
USD5.87	3000							
USD5.90	3000							
d)	Aggregated information: volume, Price	Aggregated volume: 6000 Aggregated price: USD5.887						
e)	Date of the transaction	2019-04-29						
f)	Place of the transaction	XNMS						

1	Details of the person discharging managerial responsibilities						
a)	Name	Richard Jones					
2	Reason for the notification						
a)	Position/status	Chief Financial Officer					
b)	Initial notification/ Amendment	Initial notification					
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor						
a)	Name	Mereo BioPharma Group plc					
b)	LEI	213800U8JQHJIOS5AS09					
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted						
a)	Description of the financial instrument, type of instrument and identification code	ADS					
b)	Nature of the transaction	Purchase					
c)	Price(s) and volume(s)	<table><tr><td>Price(s)</td><td>Volume(s)</td></tr><tr><td>USD6.04</td><td>2025</td></tr></table>		Price(s)	Volume(s)	USD6.04	2025
Price(s)	Volume(s)						
USD6.04	2025						
d)	Aggregated information: volume, Price	Aggregated volume: 2025 Aggregated price: USD6.04					
e)	Date of the transaction	2019-04-29					
f)	Place of the transaction	XNMS					

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: April 30, 2019

MEREO BIOPHARMA GROUP PLC

By: /s/ Charles Sermon

Name: Charles Sermon

Title: General Counsel
